Bausch Health completed the acquisition of Durect for $413m.

Bausch Health, a global, diversified pharmaceutical company, completed the acquisition of Durect, a late-stage biopharmaceutical company, for $413m. "This announcement is fundamental progress on our Strategic Priority - Innovation, which is to intensify focus and operating rigor behind R&D and business development and demonstrates our commitment to hepatology and finding new ways to address unmet medical needs, living our purpose of enriching lives through our relentless drive to deliver better health outcomes for patients," Thomas J. Appio, Bausch Health CEO.